Search

Your search keyword '"Lee, Choong-kun"' showing total 290 results
Start Over Author "Lee, Choong-kun"
290 results on '"Lee, Choong-kun"'

3. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Author

Oh, Do-Youn, He, Aiwu Ruth, Bouattour, Mohamed, Okusaka, Takuji, Qin, Shukui, Chen, Li-Tzong, Kitano, Masayuki, Lee, Choong-kun, Kim, Jin Won, Chen, Ming-Huang, Suksombooncharoen, Thatthan, Ikeda, Masafumi, Lee, Myung Ah, Chen, Jen-Shi, Potemski, Piotr, Burris, Howard A, III, Ostwal, Vikas, Tanasanvimon, Suebpong, Morizane, Chigusa, Zaucha, Renata E, McNamara, Mairéad G, Avallone, Antonio, Cundom, Juan E, Breder, Valeriy, Tan, Benjamin, Shimizu, Satoshi, Tougeron, David, Evesque, Ludovic, Petrova, Mila, Zhen, David B, Gillmore, Roopinder, Gupta, Vineet Govinda, Dayyani, Farshid, Park, Joon Oh, Buchschacher, Gary L, Jr, Rey, Felipe, Kim, Hyosung, Wang, Julie, Morgan, Claire, Rokutanda, Nana, Żotkiewicz, Magdalena, Vogel, Arndt, and Valle, Juan W

Published
2024
Full Text
View/download PDF

7. Angiopoietin-2-integrin α5β1 signaling enhances vascular fatty acid transport and prevents ectopic lipid-induced insulin resistance.

Author

Bae, Hosung, Hong, Ki Yong, Lee, Choong-Kun, Jang, Cholsoon, Lee, Seung-Jun, Choe, Kibaek, Offermanns, Stefan, He, Yulong, Lee, Hyuek Jong, and Koh, Gou Young

Abstract

Proper storage of excessive dietary fat into subcutaneous adipose tissue (SAT) prevents ectopic lipid deposition-induced insulin resistance, yet the underlying mechanism remains unclear. Here, we identify angiopoietin-2 (Angpt2)-integrin α5β1 signaling as an inducer of fat uptake specifically in SAT. Adipocyte-specific deletion of Angpt2 markedly reduced fatty acid uptake and storage in SAT, leading to ectopic lipid accumulation in glucose-consuming organs including skeletal muscle and liver and to systemic insulin resistance. Mechanistically, Angpt2 activated integrin α5β1 signaling in the endothelium and triggered fatty acid transport via CD36 and FATP3 into SAT. Genetic or pharmacological inhibition of the endothelial integrin α5β1 recapitulated adipocyte-specific Angpt2 knockout phenotypes. Our findings demonstrate the critical roles of Angpt2-integrin α5β1 signaling in SAT endothelium in regulating whole-body fat distribution for metabolic health and highlight adipocyte-endothelial crosstalk as a potential target for prevention of ectopic lipid deposition-induced lipotoxicity and insulin resistance.

Published
2020

8. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Akce, Mehmet, Ales Diaz, Inmaculada, Alves, Gustavo, Anand, Sumitra, Arslan, Cagatay, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Bai, Li-Yuan, Bai, Yuxian, Barajas, Olga, Bates, Susan, Begbie, Stephen, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Blanc, Jean-Frederic, Borbath, Ivan, Bordonaro, Robert, Bouattour, Mohamed, Brandi, Giovanni, Burgoyne, Adam, Butthongkomvong, Kritiya, Camandaroba, Marcos, Cao, Ke, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Ming-Huang, Chen, Xiaoming, Cheng, Ashley, Chiu, Tai-Jan, Choi, Hye Jin, Chon, Hong Jae, Collignon, Joelle, Cubillo Gracian, Antonio, Davis, Sarah, de Carvalho, Ricardo Saraiva, de Groot, D.J.A., Demols, Anne, De Vos, Judith, Diab, Maria, Easaw, Jacob, Eatock, Martin, Edeline, Julien, Elias, Rawad, Eskens, Fredericus, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Gbolahan, Olumide, Geboes, Karen, Geneser, Keri-Lee, Geng, Zhimin, Geva, Ravit, Gillmore, Roopinder, Goetze, Thorsten, Gou, Hongfeng, Grasselli, Julieta, Gu, Shanzhi, Gumus, Mahmut, Haj Mohammad, Nadia, Hao, Chunyi, Harputluoglu, Hakan, Hatoum, Hassan, Heinemann, Volker, Ho, Wang Kwong, Hsu, Chiun, Hubert, Ayala, Hwang, Juneul, Inanc, Mevlude, Iseas, Soledad, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Joubert, Warren, Juengsamarn, Jitlada, Kaen, Diego, Kanai, Masashi, Kasper-Virchow, Stefan, Kazemi, Ghazaleh, Kelleher, Fergal, Kelley, Robin, Kim, Jin Won, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Klumpen, Heinz, Kochenderfer, Mark, Kose, Fatih, Lam, Ho Ching, Lee, Choong-kun, Lee, Hyun Woo, Lee, Margaret, Lee, Myung Ah, Lee, Wai Man Sarah, Le Sourd, Samuel, Li, Dongliang, Li, Wei, Liang, Houjie, Liang, Tingbo, Lim, Chun Sen, Lingerfelt, Brian, Lopez, Charles, Low, John, Macarulla Mercade, Teresa, Malka, David, Mao, Yimin, Masi, Gianluca, McCune, Steven, McDermott, Ray, McWhirter, Elaine, Mendez, Guillermo, Milella, Michele, Mizuno, Nobumasa, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Nervi, Bruno, Ngamphaiboon, Nuttapong, Oh, Sang Cheul, Oksuzoglu, Berna, Outlaw, Darryl, Ozaka, Masato, Ozguroglu, Mustafa, Ozyilkan, Ozgur, Painemal, Claudio, Pan, Yueyin, Park, Joon Oh, Pelzer, Uwe, Peng, Chuang, Petorin, Caroline, Pezet, Denis, Power, Derek, Qin, Shukui, Ren, Zhenggang, Roohullah, Aflah, Ryu, Hyewon, Salman, Pamela, Sasaki, Mitsuhito, Sasidharan, Rita, Satoh, Taroh, Schulze, Kornelius, Scott-Brown, Martin, Segovia, Ruben, Seufferlein, Thomas, Siena, Salvatore, Sinapi, Isabelle, Smolenschi, Cristina, Song, Tianqiang, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Stemmer, Salomon, Su, Haichuan, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tan, Chih Kiang, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tortora, Giampaolo, Tsuji, Akihito, Ueno, Makoto, Uribe, Rodrigo, Venerito, Marino, Verdaguer Mata, Helena, Verslype, Chris, Victorino, Ana Paula, Vogel, Arndt, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Wasan, Harpeet, Weschenfelder, Rui, Wong, Chun Yin, Wong, Yoke Fui, Yalcin, Suayib, Yanez Weber, Patricio, Yang, Xuezhong, Yasui, Hisateru, Yau, Thomas, Yazici, Ozan, Yen, Chia-Jui, Ying, Jieer, Yoo, Changhoon, Yu, Wenchang, Zhao, Haitao, Kelley, Robin Kate, Finn, Richard S, Klümpen, Heinz-Josef, Chan, Stephen L, Valle, Juan W, Yu, Li, Malhotra, Usha, and Siegel, Abby B

Published
2023
Full Text
View/download PDF

14. Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment.

Author

Lee, Choong-kun, Choo, Jeong Min, Ahn, Yong Chan, Kim, Jin, Rha, Sun Young, and Rim, Chai Hong

Subjects
*CANCER treatment, *CANCER research, *BIBLIOGRAPHY, *CARCINOGENESIS, *ANNIVERSARIES
Abstract

During the celebration of the 50th anniversary of the founding of the Korean Cancer Association, articles published in Cancer Research and Treatment from 2004 to 2023 were assessed based on the subject and design of each study. Based on this analysis, trends in domestic cancer research were inferred and directions were suggested for the future development of Cancer Research and Treatment. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

16. Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13).

Author

Koo, Dong-Hoe, Jung, Minkyu, Kim, Yeul Hong, Jeung, Hei-Cheul, Zang, Dae Young, Bae, Woo Kyun, Kim, Hyunki, Kim, Hyo Song, Lee, Choong-kun, Kwon, Woo Sun, Chung, Hyun Cheol, and Rha, Sun Young

Subjects
EPIDERMAL growth factor receptors, ALANINE aminotransferase, ASPARTATE aminotransferase, OVERALL survival, ANTINEOPLASTIC agents
Abstract

Purpose: Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC). Materials and Methods: Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity. Results: RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D. Conclusion: A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Reply to B. Freidlin et al

Author

Lee, Choong-kun, primary, Park, Sejung, additional, Nam, Chung Mo, additional, Chung, Hyun Cheol, additional, and Rha, Sun Young, additional

Published
2024
Full Text
View/download PDF

20. Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

Author

Kim, Miso, primary, Shim, Hyo Sup, additional, Kim, Sheehyun, additional, Lee, In Hee, additional, Kim, Jihun, additional, Yoon, Shinkyo, additional, Kim, Hyung-Don, additional, Park, Inkeun, additional, Jeong, Jae Ho, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Kim, In-Ho, additional, Lee, Jieun, additional, Hong, Sook Hee, additional, Park, Sehhoon, additional, Jung, Hyun Ae, additional, Kim, Jin Won, additional, Kim, Han Jo, additional, Cha, Yongjun, additional, Lim, Sun Min, additional, Kim, Han Sang, additional, Lee, Choong-Kun, additional, Kim, Jee Hung, additional, Chun, Sang Hoon, additional, Yun, Jina, additional, Park, So Yeon, additional, Lee, Hye Seung, additional, Cho, Yong Mee, additional, Nam, Soo Jeong, additional, Na, Kiyong, additional, Yoon, Sun Och, additional, Lee, Ahwon, additional, Jang, Kee-Taek, additional, Yun, Hongseok, additional, Lee, Sungyoung, additional, Kim, Jee Hyun, additional, and Kim, Wan-Seop, additional

Published
2024
Full Text
View/download PDF

21. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in advanced biliary tract cancer

Author

Yoo, Changhoon, primary, Bang, Yeong Hak, additional, Lee, Choong-kun, additional, Bang, Kyunghye, additional, Kim, Hyung-Don, additional, Ryoo, Baek-Yeol, additional, Kim, Kyu-pyo, additional, Jeong, Jae Ho, additional, Park, Inkeun, additional, Lee, Dong Ki, additional, Choi, Hye Jin, additional, Chung, Taek, additional, Jeon, Seung Hyuck, additional, Shin, Eui-Cheol, additional, Oum, Chiyoon, additional, Kim, Seulki, additional, Lim, Yoojoo, additional, Park, Gahee, additional, Ahn, Changho, additional, Finn, Richard, additional, Ock, Chan-Young, additional, and Shin, Jinho, additional

Published
2024
Full Text
View/download PDF

24. Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP

Author

Kim, Miso, primary, Shim, Hyo Sup, additional, Kim, Sheehyun, additional, Lee, In Hee, additional, Kim, Jihun, additional, Yoon, Shinkyo, additional, Kim, Hyung-Don, additional, Park, Inkeun, additional, Jeong, Jae Ho, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Kim, In-Ho, additional, Lee, Jieun, additional, Hong, Sook Hee, additional, Park, Sehhoon, additional, Jung, Hyun Ae, additional, Kim, Jin Won, additional, Kim, Han Jo, additional, Cha, Yongjun, additional, Lim, Sun Min, additional, Kim, Han Sang, additional, Lee, Choong-kun, additional, Kim, Jee Hung, additional, Chun, Sang Hoon, additional, Yun, Jina, additional, Park, So Yeon, additional, Lee, Hye Seung, additional, Cho, Yong Mee, additional, Nam, Soo Jeong, additional, Na, Kiyong, additional, Yoon, Sun Och, additional, Lee, Ahwon, additional, Jang, Kee-Taek, additional, Yun, Hongseok, additional, Lee, Sungyoung, additional, Kim, Jee Hyun, additional, and Kim, Wan-Seop, additional

Published
2023
Full Text
View/download PDF

26. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study

Author

Lee, Choong-kun, primary, Kim, Hyo Song, additional, Jung, Minkyu, additional, Kim, Hyunki, additional, Bae, Woo Kyun, additional, Koo, Dong-Hoe, additional, Jeung, Hei Cheul, additional, Park, Sook Ryun, additional, Hwang, In Gyu, additional, Zang, Dae Young, additional, Lee, Hyun Woo, additional, Park, Sejung, additional, Nam, Chung Mo, additional, Chung, Hyun Cheol, additional, and Rha, Sun Young, additional

Published
2023
Full Text
View/download PDF

27. Plain Language Summary of the TOPAZ-1 Study: Durvalumab and Chemotherapy for Advanced Biliary Tract Cancer

Author

Oh, Do-Youn, primary, He, Aiwu Ruth, additional, Qin, Shukui, additional, Chen, Li-Tzong, additional, Okusaka, Takuji, additional, Vogel, Arndt, additional, Kim, Jin Won, additional, Suksombooncharoen, Thatthan, additional, Lee, Myung Ah, additional, Kitano, Masayuki, additional, Burris, Howard, additional, Bouattour, Mohamed, additional, Tanasanvimon, Suebpong, additional, McNamara, Mairead G., additional, Zaucha, Renata, additional, Avallone, Antonio, additional, Tan, Benjamin, additional, Cundom, Juan, additional, Lee, Choong-kun, additional, Takahashi, Hidenori, additional, Ikeda, Masafumi, additional, Chen, Jen-Shi, additional, Wang, Julie, additional, Makowsky, Mallory, additional, Rokutanda, Nana, additional, Żotkiewicz, Magdalena, additional, Kurland, John F., additional, Cohen, Gordon, additional, and Valle, Juan W., additional

Published
2023
Full Text
View/download PDF

28. Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer

Author

Kim, Chang Gon, primary, Jung, Minkyu, additional, Kim, Hyo Song, additional, Lee, Choong-kun, additional, Jeung, Hei-Cheul, additional, Koo, Dong-Hoe, additional, Bae, Woo Kyun, additional, Zang, Dae Young, additional, Kim, Bum Jun, additional, Kim, Hyunki, additional, Yun, Un-Jung, additional, Che, Jingmin, additional, Park, Sejung, additional, Kim, Tae Soo, additional, Kwon, Woo Sun, additional, Park, Juin, additional, Cho, Sang Woo, additional, Nam, Chung Mo, additional, Chung, Hyun Cheol, additional, and Rha, Sun Young, additional

Published
2023
Full Text
View/download PDF

32. Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study

Author

Baek, Yae Jee, primary, Lee, Youn-Jung, additional, Park, So Ra, additional, Kim, Kyoo Hyun, additional, Beom, Seung-Hoon, additional, Lee, Choong-kun, additional, Shin, Sang Joon, additional, Rha, Sun Young, additional, Kim, Sinyoung, additional, Lee, Kyoung Hwa, additional, Kim, Jung Ho, additional, Jeong, Su Jin, additional, Ku, Nam Su, additional, Choi, Jun Yong, additional, Yeom, Joon-Sup, additional, Jung, Minkyu, additional, and Ahn, Jin Young, additional

Published
2023
Full Text
View/download PDF

37. Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer.

Author

Lee, Kwang Seob, Lee, Choong-Kun, Kwon, Soon Sung, Kwon, Woo Sun, Park, Sejung, Lee, Seung-Tae, Choi, Jong Rak, Rha, Sun Young, and Shin, Saeam

Subjects
*CELL-free DNA, *STOMACH cancer, *CANCER patients, *HEMATOPOIESIS, *SINGLE nucleotide polymorphisms, *DNA fingerprinting
Abstract

Clonal hematopoiesis (CH) is a condition in which healthy individuals have somatic mutations in hematopoietic stem cells. It has been reported with increased risk of hematologic malignancy and cardiovascular disease in the general population, but studies of Korean populations with comorbid disease entities are scarce. White blood cells (WBCs) from patients with gastric cancer (GC) (n=121) were analyzed using a DNA-based targeted (531 genes) panel with customized pipeline designed to detect single nucleotide variants and small indels with low-allele-frequency of ≥0.2 %. We defined significant CH variants as having variant allele frequency (VAF) ≥2 % among variants found in WBCs. Matched cell-free DNA (cfDNA) samples were also analyzed with the same pipeline to investigate the false-positive results caused by WBC variants in cfDNA profiling. Significant CH variants were detected in 29.8 % of patients and were associated with age and male sex. The number of CH variants was associated with a history of anti-cancer therapy and age. DNMT3A and TET2 were recurrently mutated. Overall survival rate of treatment-naïve patients with stage IV GC was higher in those with CH, but Cox regression showed no significant association after adjustment for age, sex, anti-cancer therapy, and smoking history. In addition, we analyzed the potential interference of WBC variants in plasma cell-free DNA testing, which has attracted interest as a complementary method for tissue biopsy. Results showed that 37.0 % (47/127) of plasma specimens harbored at least one WBC variant. VAFs of interfering WBC variants in the plasma and WBC were correlated, and WBC variants with VAF ≥4 % in WBC were frequently detected in plasma with the same VAF. This study revealed the clinical impact of CH in Korean patients and suggests the potential for its interference in cfDNA tests. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer

Author

Lee, Sung Hwan, primary, Cheon, Jaekyung, additional, Lee, Seoyoung, additional, Kang, Beodeul, additional, Kim, Chan, additional, Shim, Hyo Sup, additional, Park, Young Nyun, additional, Jung, Sanghoon, additional, Choi, Sung Hoon, additional, Choi, Hye Jin, additional, Lee, Choong-kun, additional, and Chon, Hong Jae, additional

Published
2023
Full Text
View/download PDF

39. Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

Author

Yoo, Changhoon, primary, Javle, Milind M., additional, Verdaguer Mata, Helena, additional, de Braud, Filippo, additional, Trojan, Jörg, additional, Raoul, Jean-Luc, additional, Kim, Jin Won, additional, Ueno, Makoto, additional, Lee, Choong-kun, additional, Hijioka, Susumu, additional, Cubillo, Antonio, additional, Furuse, Junji, additional, Azad, Nilofer, additional, Sato, Masashi, additional, Vugmeyster, Yulia, additional, Machl, Andreas, additional, Bajars, Marcis, additional, Bridgewater, John, additional, Oh, Do-Youn, additional, and Borad, Mitesh J., additional

Published
2023
Full Text
View/download PDF

40. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Kelley, Robin Kate, primary, Ueno, Makoto, additional, Yoo, Changhoon, additional, Finn, Richard S, additional, Furuse, Junji, additional, Ren, Zhenggang, additional, Yau, Thomas, additional, Klümpen, Heinz-Josef, additional, Chan, Stephen L, additional, Ozaka, Masato, additional, Verslype, Chris, additional, Bouattour, Mohamed, additional, Park, Joon Oh, additional, Barajas, Olga, additional, Pelzer, Uwe, additional, Valle, Juan W, additional, Yu, Li, additional, Malhotra, Usha, additional, Siegel, Abby B, additional, Edeline, Julien, additional, Vogel, Arndt, additional, Akce, Mehmet, additional, Ales Diaz, Immaculada, additional, Alves, Gustavo, additional, Anand, Sumitra, additional, Arslan, Cagatay, additional, Asselah, Jamil, additional, Assenat, Eric, additional, Aubin, Francine, additional, Bai, Li-Yuan, additional, Bai, Yuxian, additional, Bates, Susan, additional, Begbie, Stephen, additional, Ben-Aharon, Irit, additional, Beri, Nina, additional, Berres, Marie-Luise, additional, Blanc, Jean-Frederic, additional, Borbath, Ivan, additional, Bordonaro, Robert, additional, Brandi, Giovanni, additional, Burgoyne, Adam, additional, Butthongkomvong, Kritiya, additional, Cao, Ke, additional, Carballido, Marcela, additional, Camandaroba, Marcos, additional, Chang, Stephan Lam, additional, Chen, Jen-Shi, additional, Chen, Ming-Huang, additional, Chen, Xiaoming, additional, Cheng, Ashley, additional, Chiu, Tai-Jan, additional, Choi, Hye Jin, additional, Chon, Hong Jae, additional, Collignon, Joelle, additional, Cubillo Gracian, Antonio, additional, Davis, Sarah, additional, de Carvalho, Ricardo Saraiva, additional, de Groot, D.J.A., additional, Demols, Anne, additional, De Vos, Judith, additional, Diab, Maria, additional, Easaw, Jacob, additional, Eatock, Martin, additional, Elias, Rawad, additional, Eskens, Fredericus, additional, Falcone, Alfredo, additional, Fernandez, Plinio, additional, Finn, Richard, additional, Franke, Fabio, additional, Furukawa, Masayuki, additional, Gbolahan, Olumide, additional, Geboes, Karen, additional, Geneser, Keri-Lee, additional, Geng, Zhimin, additional, Geva, Ravit, additional, Gillmore, Roopinder, additional, Goetze, Thorsten, additional, Gou, Hongfeng, additional, Grasselli, Julieta, additional, Gu, Shanzhi, additional, Gumus, Mahmut, additional, Haj Mohammad, Nadia, additional, Hao, Chunyi, additional, Harputluoglu, Hakan, additional, Hatoum, Hassan, additional, Heinemann, Volker, additional, Ho, Wang Kwong, additional, Hsu, Chiun, additional, Hubert, Ayala, additional, Hwang, Juneul, additional, Inanc, Mevlude, additional, Iseas, Soledad, additional, Jeyasingam, Vaishnavi, additional, Jimenez Fonseca, Paula, additional, Joubert, Warren, additional, Juengsamarn, Jitlada, additional, Kaen, Diego, additional, Kanai, Masahi, additional, Kasper-Virchow, Stefan, additional, Kazemi, Ghazaleh, additional, Kelleher, Fergal, additional, Kelley, Robin, additional, Kim, Jin Won, additional, Kim, Jong Gwang, additional, Kinupe Abrahao, Ana Beatriz, additional, Klumpen, Heinz, additional, Kochenderfer, Mark, additional, Kose, Fatih, additional, Lam, Ho Ching, additional, Lee, Choong-kun, additional, Lee, Hyun Woo, additional, Lee, Margaret, additional, Lee, Myung Ah, additional, Lee, Wai Man Sarah, additional, Le Sourd, Samuel, additional, Li, Dongliang, additional, Li, Wei, additional, Liang, Houjie, additional, Liang, Tingbo, additional, Lim, Chun Sen, additional, Lingerfelt, Brian, additional, Lopez, Charles, additional, Low, John, additional, Macarulla Mercade, Teresa, additional, Malka, David, additional, Mao, Yimin, additional, Masi, Gianluca, additional, McCune, Steven, additional, McDermott, Ray, additional, McWhirter, Elaine, additional, Mendez, Guillermo, additional, Milella, Michele, additional, Mizutani, Tomonori, additional, Moniz, Camila, additional, Morales, Luisa, additional, Munoz Martin, Andres Jesús, additional, Nervi, Bruno, additional, Ngamphaiboon, Nuttapong, additional, Oh, Sang Cheul, additional, Oksuzoglu, Berna, additional, Outlaw, Darryl, additional, Ozguroglu, Mustafa, additional, Ozyilkan, Ozgur, additional, Painemeal, Claudio, additional, Pan, Yueyin, additional, Peng, Chuang, additional, Petorin, Caroline, additional, Pezet, Denis, additional, Power, Derek, additional, Qin, Shukui, additional, Roohullah, Aflah, additional, Ryu, Hyewon, additional, Salman, Pamela, additional, Sasidharan, Rita, additional, Satho, Taroh, additional, Schulze, Kornelius, additional, Scott-Brown, Martin, additional, Segovia, Ruben, additional, Seufferlin, Thomas, additional, Siena, Salvatore, additional, Sinapi, Isabelle, additional, Smolenschi, Cristina, additional, Song, Tianqiang, additional, Sookprasert, Aumkhae, additional, Soparattanapaisarn, Nopadol, additional, Starling, Naureen, additional, Stein, Stacey, additional, Stemmer, Salomon, additional, Su, Haichuan, additional, Sugimoto, Rie, additional, Suksombooncharoen, Thatthan, additional, Tam, Vincent, additional, Tan, Ai Lian, additional, Tan, Chih Kiang, additional, Tanasanvimon, Suebpong, additional, Tonini, Giuseppe, additional, Tortora, Giampaolo, additional, Tsuji, Akihito, additional, Uribe, Rodrigo, additional, Venerito, Marino, additional, Verdaguer Mata, Helena, additional, Victorino, Ana Paula, additional, Wade, James, additional, Waldschmidt, Dirk Thomas, additional, Wang, Lu, additional, Wan Isahk, Wan Zamaniah, additional, Wasan, Harpeet, additional, Weschenfelder, Rui, additional, Wong, Chun Yin, additional, Wong, Yoke Fui, additional, Yalcin, Suayib, additional, Yanez Weber, Patricio, additional, Yang, Xuezhong, additional, Yasui, Hisateru, additional, Yazici, Ozan, additional, Yen, Chia-Jui, additional, Ying, Jieer, additional, Yu, Wenchang, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

42. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma

Author

Kim, Jaeryung, Park, Dae-Young, Bae, Hosung, Park, Do Young, Kim, Dongkyu, Lee, Choong-Kun, Song, Sukhyun, Chung, Tae-Young, Lim, Dong Hui, Kubota, Yoshiaki, Hong, Young-Kwon, He, Yulong, Augustin, Hellmut G., Oliver, Guillermo, and Koh, Gou Young

Subjects
Diagnosis, Care and treatment, Research, Intraocular pressure -- Research, Glaucoma -- Diagnosis -- Care and treatment, Blood vessels -- Research
Abstract

Introduction Glaucoma is a leading cause of irreversible blindness, affecting 3.5% of the population aged 40 to 80 years worldwide (1). It involves cupping of the optic nerve head and [...], Primary open-angle glaucoma (POAG) is often caused by elevated intraocular pressure (IOP), which arises due to increased resistance to aqueous humor outflow (AHO). Aqueous humor flows through Schlemm's canal (SC), a lymphatic-like vessel encircling the cornea, and via intercellular spaces of ciliary muscle cells. However, the mechanisms underlying increased AHO resistance are poorly understood. Here, we demonstrate that signaling between angiopoietin (Angpt) and the Angpt receptor Tie2, which is critical for SC formation, is also indispensable for maintaining SC integrity during adulthood. Deletion of Angpt1/Angpt2 or Tie2 in adult mice severely impaired SC integrity and transcytosis, leading to elevated IOP, retinal neuron damage, and impairment of retinal ganglion cell function, all hallmarks of POAG in humans. We found that SC integrity is maintained by interconnected and coordinated functions of Angpt-Tie2 signaling, AHO, and Prox1 activity. These functions diminish in the SC during aging, leading to impaired integrity and transcytosis. Intriguingly, Tie2 reactivation using a Tie2 agonistic antibody rescued the POAG phenotype in Angpt1/Angpt2-deficient mice and rejuvenated the SC in aged mice. These results indicate that the Angpt-Tie2 system is essential for SC integrity. The impairment of this system underlies POAGassociated pathogenesis, supporting the possibility that Tie2 agonists could be a therapeutic option for glaucoma.

Published
2017
Full Text
View/download PDF

43. A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.

Author

Park, Joon Oh, primary, Park, Joon Seong, additional, Lee, Choong-kun, additional, Chon, Hong Jae, additional, Choi, Sae Byeol, additional, Hwang, Dae Wook, additional, Oh, Do-Youn, additional, Lee, Myung Ah, additional, Jang, Jin-Young, additional, and Ryoo, Baek-Yeol, additional

Published
2023
Full Text
View/download PDF

44. Clinical application of circulating tumor DNA (ctDNA) in patients with metastatic gastric cancer.

Author

Hong, Moonki, primary, Lee, Kwang Seob, additional, Park, Sejung, additional, Kim, Kyoo Hyun, additional, Kim, Hyunwook, additional, Che, Jingmin, additional, Kwon, Woo Sun, additional, Lee, Choong-kun, additional, Jung, Minkyu, additional, Chung, Hyun Cheol Cheol, additional, Shin, Saeam, additional, Lee, Seung-Tae, additional, Choi, Jong Rak, additional, and Rha, Sun Young, additional

Published
2023
Full Text
View/download PDF

50. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries

Author

Lee, Choong-kun, Yoo, Changhoon, Hong, Jung Yong, Park, Se Jun, Kim, Jin Won, Tai, David Wai Meng, Kim, Hyeyeong, Korphaisarn, Krittiya, Tanasanvimon, Suebpong, Chen, San-Chi, Kim, Ju Won, Kim, Ilhwan, Kim, Moonho, Choo, Joan, Oh, Sang-Bo, Chen, Ching-Tso, Bae, Woo Kyun, Kim, Hongsik, Huh, Seok Jae, Yen, Chia-Jui, Park, Sejung, Lee, Dong Ki, Chan, Landon Long, Kang, Beodeul, Kang, Minsu, Sundar, Raghav, Choi, Hye Jin, Chan, Stephen Lam, Chon, Hong Jae, and Lee, Myung-Ah

Abstract

Introduction:Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients with HCC who progressed on first-line atezolizumab plus bevacizumab remain unclear. Methods:This multinational, multi-institutional, retrospective study included patients with HCC from 22 centers in five Asia-Pacific countries who were treated with first-line atezolizumab plus bevacizumab, which was discontinued for any reason. The endpoints included progression-free survival (PFS) and overall survival (OS) according to patient characteristics and second-line regimens. Results:Between June 2016 and May 2023, 1,141 patients were treated with first-line atezolizumab plus bevacizumab, of whom 629 (55.1%) received subsequent treatment. Sorafenib and lenvatinib were the most commonly administered second-line regimens (53.9% and 25.6%, respectively). Overall, the median PFS and OS were 2.9 and 8.0 months, respectively. Lenvatinib had longer PFS (4.0 vs. 2.3 months) and OS (8.0 vs. 6.3 months) than sorafenib. Patients treated with tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) (n= 50, 8.3%) showed PFS and OS of 5.4 and 12.6 months, respectively. Lower tumor burden and lenvatinib or TKI plus ICI use were associated with longer second-line PFS. Preserved liver function was associated with improved OS. Conclusions:In patients with HCC who progressed on first-line atezolizumab plus bevacizumab, sorafenib and lenvatinib were the most commonly used second-line regimens in Asia-Pacific countries, with lenvatinib resulting in longer OS than sorafenib. The second-line TKI plus ICI combination exhibited promising efficacy, suggesting the potential role of continuing ICIs beyond disease progression.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results